Risk Factor Pregnancy:
No evidence of risk in humans. Lactation: Contraindicated or not recommended. Precautions: Exclude malignant disease before and during treatment. Impaired renal or hepatic function, increased risk of GI infection. Monitor patients on long term therapy.
Indications Erosive reflux oesophagitis, prevention of relapse of oesophagitis, symptomatic treatment of GERD. Zollinger-Ellison syndrome, severe peptic ulcer bleeding (following endoscopic treatment). In combination with antibiotics for the eradication of H. pylori, healing of H. pylori-associated duodenal ulcer and prevention of relapse of H. pylori-associated peptic ulcers. Treatment and prevention of NSAID-associated peptic ulceration. Dosage ORAL: Adults: Erosive oesophagitis: 40 mg once daily for 4-8 wk. Prevention of relapse, 20 mg once daily. GERD without oesophagitis: 20 mg once daily for 4 wk. Maintenance, 20 mg once daily as required. Zollinger-Ellison syndrome: Initially 40 mg two times daily. can be altered according to